Zoetis Inc. $ZTS Shares Purchased by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 35.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,004,211 shares of the company’s stock after buying an additional 260,909 shares during the quarter. Artisan Partners Limited Partnership owned approximately 0.23% of Zoetis worth $146,936,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. Norges Bank purchased a new position in shares of Zoetis in the 2nd quarter valued at about $809,491,000. Diamond Hill Capital Management Inc. acquired a new position in Zoetis in the third quarter valued at approximately $394,010,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after purchasing an additional 1,995,491 shares during the last quarter. Corient Private Wealth LLC raised its holdings in Zoetis by 85.9% during the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after purchasing an additional 1,191,840 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its position in shares of Zoetis by 362.6% during the 2nd quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock worth $182,705,000 after buying an additional 922,589 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of ZTS opened at $129.65 on Friday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock’s 50 day moving average is $125.88 and its two-hundred day moving average is $134.28. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.00. The firm has a market capitalization of $54.73 billion, a PE ratio of 21.54, a P/E/G ratio of 1.97 and a beta of 0.96.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same period last year, the firm earned $1.40 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is presently 35.22%.

Analyst Ratings Changes

A number of research analysts recently commented on ZTS shares. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. KeyCorp assumed coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock. Morgan Stanley set a $160.00 target price on Zoetis in a report on Thursday, December 18th. HSBC set a $140.00 target price on Zoetis in a research report on Wednesday, December 10th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.